HIV Vaccine Trial in Thai Adults

Clinical Trial ID NCT00223080

PubWeight™ 62.58‹?›

🔗 Visit the page for NCT00223080

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009 28.62
2 Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012 12.98
3 Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004 2.01
4 Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One 2014 1.97
5 Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005 1.96
6 Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One 2013 1.94
7 Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One 2013 1.65
8 COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 2015 1.14
9 Editorial neuroAIDS review. AIDS 2011 1.10
10 Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. J Virol 2014 1.03
11 Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 2013 0.97
12 Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One 2011 0.93
13 Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses. EBioMedicine 2014 0.92
14 Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol 2012 0.92
15 HIV-1 envelope resistance to proteasomal cleavage: implications for vaccine induced immune responses. PLoS One 2012 0.92
16 HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. Sci Transl Med 2015 0.81
17 RNA interference approaches for treatment of HIV-1 infection. Genome Med 2015 0.81
18 Combinatorial RNA-based gene therapy for the treatment of HIV/AIDS. Expert Opin Biol Ther 2013 0.81
19 HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. Nat Med 2015 0.80
20 Identification of immunodominant CD4-restricted epitopes co-located with antibody binding sites in individuals vaccinated with ALVAC-HIV and AIDSVAX B/E. PLoS One 2015 0.79
21 siRNA-based topical microbicides targeting sexually transmitted infections. Curr Opin Mol Ther 2010 0.79
22 HIV-specific Th2 and Th17 responses predict HIV vaccine protection efficacy. Sci Rep 2016 0.77
23 Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor. PLoS One 2015 0.77
24 Foundations for a Phase III human immunodeficiency virus vaccine trial: A decade of Thai-U.S. Army collaborative research. Mil Med 2004 0.75
25 Jury still out on HIV vaccine results. Nature 2009 0.75
26 Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine 2017 0.75
27 HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One 2016 0.75
28 CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. PLoS One 2014 0.75
29 Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. PLoS One 2015 0.75
Next 100